Drug
FDA grants 7-year orphan drug exclusivity period for Tarpeyo
The FDA has granted a 7-year orphan drug exclusivity period for Tarpeyo, a medication for the treatment of primary immunoglobulin A nephropathy, according to a press release.
Endocrinology Drug and Device Update
In a review of the 2023 milestones, Healio | Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared or had label or indication changes. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omission. Appearance of a drug or device does not constitute any endorsement by Healio | Endocrine Today, its editors, publishers or editorial board. – The Editors
Journey Medical enters up to $20 million credit facility for potential rosacea drug launch
Journey Medical Corporation’s efforts to launch a new rosacea drug have received a boost of up to $20 million as the company has entered into a credit facility with an affiliate of SWK Holdings Corporation.
‘Eye opening’ number of children exposed to major drug interactions, study finds
More than one in five children on Medicaid are exposed to at least one major drug interaction annually, according to findings from a study published in Pediatrics.
Experts determine best management for drug reaction with eosinophilia, systemic symptoms
Experts weighed in on the best ways to treat mild to severe drug reaction with eosinophilia and systemic symptoms, according to a study.
‘All hands on deck’ needed to navigate oncology drug shortages, says expert panel
A virtual town hall meeting featuring a panel of regulatory, pharmacy and procurement experts addressed the ongoing shortage of oncology drugs.
Akebia gets FDA review date of March 2024 for anemia drug vadadustat
The FDA has set a user fee goal date of March 27, 2024, for review of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat for the treatment of anemia in adults on dialysis.
Spacecraft experimenting with HIV drug denied reentry to US
A spacecraft being used to manufacture a crystalized version of the HIV drug ritonavir in low Earth orbit has been denied reentry and permission to land in the United States, Healio confirmed.
CDC gives $279M toward reducing drug overdoses in US
The CDC has awarded $279 million to 49 states, the District of Columbia and 40 local health departments to address rising drug overdoses in communities, the agency announced.
Evelo restructures second-quarter finances to carry drug candidate through phase 2 trial
Evelo Biosciences announced that it has accumulated enough financial resources to take its psoriasis drug candidate past the phase 2 clinical readout, according to the company’s second-quarter 2023 financial results.